Syneos Health in a new report suggests payers are more reluctant to use real-world evidence (RWE) in reimbursement and formulary decisions despite rising interest among other organizations.
“Our research reveals that payers are positively disposed to use RWE, but knowledge gaps around the validity and value of RWE must be closed to improve access for rare disease patients,” Syneos Health CEO Alistair Macdonald said in a statement. “Multistakeholder feedback points to the need for collaborative, well-structured exercises and standard-setting for payers to advance at the same velocity as other industry stakeholders. Dialogue is key, and the time to facilitate these conversations is now.”
To read more, click here.